Skip to main content
. 2021 Aug 5;2(4):576–585. doi: 10.1093/ehjdh/ztab071

Table 2.

The table summarizes the META data statistics

C0 C1 C2 P-value
Age years, mean SD 72.00 (12.98) 72.00 (13.17) 55.00 (16.27) <0.001*
Amiodarone, n (%) 197 (2.73) 165 (2.53) 2013 (0.51) <0.001*
Diuretics, n (%) 2334 (32.3) 2072 (31.78) 85 025 (21.36) <0.001*
Sex, male, n (%) 4011 (55.52) 3361 (51.55) 149 755 (37.61) <0.001*
PAH, n (%) 3504 (48.5) 3198 (49.05) 143 902 (36.14) <0.001*
Chagas, n (%) 432 (5.98) 384 (5.86) 9634 (2.42) <0.001*
Beta blockers, n (%) 878 (12.15) 740 (11.35) 31 419 (7.89) <0.001*
Family CHD, n (%) 1005 (13.91) 923 (14.16) 50 140 (12.59) <0.001*
MI, n (%) 121 (1.67) 95 (1.46) 3207 (0.81) <0.001*
COPD, n (%) 86 (1.19) 57 (0.87) 2423 (0.61) <0.001*
DM, n (%) 561 (7.76) 542 (8.31) 28 633 (7.19) <0.001*
Obesity, n (%) 335 (4.64) 391 (6.0) 22 868 (5.74) 0.001*
Dyslipidaemia, n (%) 287 (3.97) 268 (4.11) 15 363 (3.86) 0.031*
Calcium blockers, n (%) 0 (0.0) 0 (0.00) 95 (0.01) 0.155
Smoking, n (%) 367 (5.08) 387 (5.94) 24 627 (6.19) 0.486

It includes a summary for the baseline recordings in C0, C1, C2. With examples in C0 being AF, examples in C1 developing AF within 5 years and examples in C2 not developing AF within 5 years. Mann–Whitney rank test was performed between C1 and C2. Features ordered from most to least significant according to their P-value. The sign * indicates statistical significance (Mann–Whitney rank test, P < 0.05).